GSK, the top 10 pharmaceutical company with global market value, slipped out of the list in 2017

Source: Pharmaceutical representative 2017-12-1 Gen (genetic engineering and biotechnology news magazine), founded in 1981, is a world-famous authoritative biotechnology media On November 27, Gen website published the 2017 top 10 pharmaceutical enterprises by market value The following is the list of top 10 pharmaceutical companies this year According to the market value as of November 9, 2017, the data comes from the company's website, stock trading website and other public channels The data of non-U.S companies are converted into US dollars according to the exchange rate of that day Top 10 pharmaceutical companies with the highest market value in the world (unit: US $100 million) pharmaceutical companies are relatively smooth overall, most of the traditional pharmaceutical companies are more successful than biotechnology companies this year When biotechnology companies fall into the disappointments of clinical trials or failure in Q3, most of the pharmaceutical companies look smooth this year As of November 9, 2017, the Arca Pharmaceutical Stock Index of New York Stock Exchange increased by 7.8% to $536.86 compared with the same period last year, while the market value of top 10 pharmaceutical companies in Gen's list reached $1.722 trillion this year, an increase of 9.8% compared with $1.568 trillion of top 10 companies last year, and an increase of 5.9% compared with $1.626 trillion of top 10 companies in 2015 Gen explained this reason with five factors: • the sales of heavy bomb drugs with an annual sales volume of more than US $1 billion continued to grow; • under the leadership of Scott Gottlieb, the new director of FDA, simplified the new drug listing procedures, and more new drugs were approved; • the corporate tax reduction policy launched by the trump government; • Trump's policy on reducing drug prices was not implemented as scheduled; • pharmaceutical companies shift from large-scale M & A to small-scale reinforcement acquisition GSK slipped out of the list Compared with last year, only one company, GlaxoSmithKline (No 6 in 2016), slipped out of the list this year, with a market value of 66.38 billion pounds (about 87.29 billion US dollars), 16% lower than last year's 103.82 billion US dollars Lilly company, which replaced GSK in the top 10, ranked No 11 last year with a market value of 86.63 billion US dollars What's more encouraging is that in addition to MSD, the market value of each of the top 10 pharmaceutical companies has increased this year compared with last year, and the ranking of Alberto and Bayer has been improved However, MSD dropped 1 to 6 from 2016, and was surpassed by the 7th Alberto in last year On October 27, 2017, MSD announced that Q3 revenue decreased by 2% year-on-year, from $10.536 billion in Q3 in 2016 to $10.325 billion MSD provided several reasons for the decline in revenue For example, this year, MSD suffered a cyber attack that resulted in the shutdown of 9-price jiadachou, resulting in a loss of sales revenue of $135 million, which was actually a $240 million 9-price jiadachou order for the US CDC Other reasons include a 3% drop in drug sales to US $9.2 billion, mainly due to the fact that zetia and Vytorin (ezemeb / simvastatin) are facing patent cliff, and they lost market monopoly in the United States at the end of last year and early April of this year In addition, cupicin, an antibiotic of cubist, was acquired at the end of 2014 The competition of generic drugs is also facing for the injection of daptomycin REMICADE (infliximab) is also facing the competition of bio generic drugs in Europe.